It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Neutrophil diapedesis is an immediate step following infections and injury and is driven by complex interactions between leukocytes and various components of the blood vessel wall. Here, we show that perivascular mast cells (MC) are key regulators of neutrophil behaviour within the sub-endothelial space of inflamed venules. Using confocal intravital microscopy, we observe directed abluminal neutrophil motility along pericyte processes towards perivascular MCs, a response that created neutrophil extravasation hotspots. Conversely, MC-deficiency and pharmacological or genetic blockade of IL-17A leads to impaired neutrophil sub-endothelial migration and breaching of the pericyte layer. Mechanistically, identifying MCs as a significant cellular source of IL-17A, we establish that MC-derived IL-17A regulates the enrichment of key effector molecules ICAM-1 and CXCL1 in nearby pericytes. Collectively, we identify a novel MC-IL-17A-pericyte axis as modulator of the final steps of neutrophil diapedesis, with potential translational implications for inflammatory disorders driven by increased neutrophil diapedesis.
The blood vessel wall is a complex multi-layered structure, yet upon injury or infection, neutrophil leukocytes are rapidly migrating from the blood stream to the affected tissues, by a process termed diapedesis. Authors here show that the final steps of diapedesis through the outer pericyte layer is regulated by perivascular mast cells via IL-17A production.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Queen Mary University of London, Charterhouse Square, William Harvey Research Institute, Faculty of Medicine and Dentistry, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133); NHLI, Imperial College London, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
2 Queen Mary University of London, Charterhouse Square, William Harvey Research Institute, Faculty of Medicine and Dentistry, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133); CINVESTAV-IPN, Department of Molecular Biomedicine, Mexico City, Mexico (GRID:grid.512574.0)
3 Queen Mary University of London, Charterhouse Square, William Harvey Research Institute, Faculty of Medicine and Dentistry, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133); University of Würzburg, Rudolf Virchow Center for Experimental Biomedicine, Würzburg, Germany (GRID:grid.8379.5) (ISNI:0000 0001 1958 8658)
4 Queen Mary University of London, Charterhouse Square, William Harvey Research Institute, Faculty of Medicine and Dentistry, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133)
5 CINVESTAV-IPN, Department of Molecular Biomedicine, Mexico City, Mexico (GRID:grid.512574.0)
6 University Hospital Erlangen and Friedrich-Alexander University Erlangen-Nuremberg (FAU), Department of Infection Biology, Erlangen, Germany (GRID:grid.411668.c) (ISNI:0000 0000 9935 6525)
7 Heidelberg University Hospital, Institute for Immunology, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)
8 Queen Mary University of London, Charterhouse Square, William Harvey Research Institute, Faculty of Medicine and Dentistry, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133); Queen Mary University of London, Centre for Inflammation and Therapeutic Innovation, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133)